Why Is TdVax So Hard to Find? [Explained for 2026]

If you or your doctor have tried to locate TdVax recently, you've likely run into a wall: the vaccine is simply no longer available. This isn't a temporary back-order or a regional supply hiccup. TdVax has been permanently discontinued, and understanding exactly what happened — and what your options are now — is critical for staying up to date on your tetanus and diphtheria protection.

What Was TdVax?

TdVax was a tetanus and diphtheria (Td) vaccine manufactured by MassBiologics, a nonprofit vaccine maker based in Massachusetts. Each 0.5 mL dose contained 2 Lf of tetanus toxoid and 2 Lf of diphtheria toxoid, adsorbed on an aluminum adjuvant. The vaccine was FDA-approved for active immunization against tetanus and diphtheria in persons 7 years of age and older and was distributed in the United States by Grifols USA.

TdVax served an important role as one of only two Td vaccines available in the United States. It was used for routine adult boosters every 10 years, for wound management after deep cuts or burns, and for patients who had a contraindication to the pertussis component in Tdap vaccines. It did not protect against pertussis (whooping cough) — that would require a Tdap vaccine like Adacel or Boostrix — but for patients who couldn't receive pertussis-containing vaccines, TdVax was the only option.

Why Did TdVax Get Discontinued?

In early 2024, MassBiologics announced it was permanently stopping production of TdVax. The company cited declining demand as the primary driver: over the past decade, most physicians had switched to stocking Tdap vaccines, which offer broader protection against tetanus, diphtheria, and pertussis, making the Td-only TdVax increasingly niche. MassBiologics' spokesperson noted that "similar vaccines have led to a reduction in demand" for TdVax.

This wasn't entirely unexpected in the vaccine industry. The market for pure Td vaccines had been shrinking for years as the CDC increasingly recommended Tdap as the default choice for adolescents and adults. The decision was also separate from an earlier regulatory issue in which MassBiologics had faced FDA scrutiny over certain manufactured lots.

Grifols USA, the sole distributor of TdVax, informed the CDC that existing supplies would last only until approximately June 2024. After that, TdVax was gone from the market entirely.

What Happened to the Td Vaccine Supply After TdVax Was Discontinued?

The fallout from TdVax's discontinuation was significant. With only one Td vaccine left on the U.S. market — Sanofi Pasteur's Tenivac — the CDC immediately implemented temporary ordering controls in both public and private sectors to conserve the remaining supply. Sanofi announced it was ramping up Tenivac production to try to fill the gap, but the transition created real disruptions for patients and providers across the country.

The CDC issued updated guidance recommending that healthcare providers use Tdap vaccines (Adacel and Boostrix) instead of Td vaccines "whenever possible" while Td supplies were constrained. This was a practical workaround, but it placed enormous new demand on the Tdap supply chain. Adacel and Boostrix began experiencing their own availability challenges as a result — a ripple effect that patients across the country felt into 2025 and 2026.

Who Is Most Affected by the Loss of TdVax?

For most adults, the discontinuation of TdVax is manageable: their physician or pharmacist can simply substitute a Tdap vaccine (Adacel or Boostrix), which provides the same tetanus and diphtheria protection plus coverage against pertussis. The CDC explicitly endorses this substitution for routine boosters and wound management.

However, a small but important group of patients truly needs a Td-only vaccine. These include:

• People who have previously experienced encephalopathy (brain damage) after a pertussis-containing vaccine, for whom additional pertussis shots are contraindicated
• Patients with a documented severe reaction to the pertussis component of prior Tdap doses
• Certain individuals whose physicians have determined Tdap is medically inadvisable

For these patients, Tenivac — now the sole remaining Td vaccine — is the only option. Given that Tenivac is operating under CDC ordering limits, locating it can require significant effort.

Is There Any Chance TdVax Will Come Back?

As of 2026, there are no indications that TdVax or any equivalent Td-only vaccine from a new manufacturer is on the horizon. MassBiologics' decision was permanent. Vaccine manufacturing is an extraordinarily capital-intensive industry, and the niche market for Td-only vaccines makes it economically unattractive for new entrants. Realistically, Tenivac will remain the sole Td vaccine in the United States for the foreseeable future.

What Should Patients Do If They Need a Td Vaccine?

If your provider has recommended a Td booster, here are your practical options in 2026:

1. Ask your provider about Tdap substitution. For most patients, the CDC endorses Adacel or Boostrix as acceptable alternatives. Tdap provides all the same tetanus and diphtheria protection, plus pertussis coverage.
2. Search for Tenivac if you truly need a Td-only vaccine. Tenivac (Sanofi's Td vaccine) is still available but may have limited supply at any given pharmacy. Call ahead or use a service that calls pharmacies for you.
3. Use medfinder. medfinder.com calls pharmacies near you to check which ones have the specific vaccine you need in stock, saving you the time and frustration of calling around yourself.
4. Try different pharmacy types. Hospital outpatient clinics, travel medicine clinics, occupational health departments, and employee health services sometimes maintain separate vaccine inventories not reflected at retail pharmacies.

How Does the TdVax Discontinuation Affect the Broader Vaccine Landscape?

The TdVax discontinuation highlighted a broader vulnerability in the U.S. vaccine supply: when only one or two manufacturers produce a critical vaccine, the exit of even one can cause nationwide supply disruptions. The ripple effects from TdVax's discontinuation cascaded into Tenivac shortages, then into elevated demand for Adacel and Boostrix, causing spot shortages of those vaccines too. Public health officials and policymakers have noted this as a systemic concern requiring long-term solutions.

For a full breakdown of what vaccine you can use instead of TdVax, read our guide: Alternatives to TdVax If You Can't Fill Your Prescription.

The Bottom Line

TdVax is permanently discontinued and will not return. If you need tetanus-diphtheria protection in 2026, your best options are Tdap vaccines (Adacel or Boostrix) for most patients, or Tenivac if you genuinely require a pertussis-free Td shot. If you're having trouble finding Tenivac or any tetanus-related vaccine at your local pharmacy, medfinder can help you locate which pharmacies near you have it in stock without the hassle of calling around yourself. Your protection against tetanus and diphtheria matters — don't let supply chain issues leave you unprotected.